Salestools LogoSalestools
Salestools AI-agenter
Lösningar
Resurser
Företag
Priser
Salestools Logo

Salestools

#1 AI-agent för säljteam och Go-to-Market-team. Sälj mer, snabbare, med mindre ansträngning.

Produkt

  • AI-säljagenter
  • Intentionsdata
  • Teknologidata
  • Besöksspårning
  • Medpilot
  • Social Försäljning

Lösningar

  • Kundservice
  • E-handel
  • SaaS
  • Företag
  • Småföretag

Resurser

  • Rapporten
  • Dokumentation
  • API-referens
  • Hjälpcenter
  • Blogg
  • Fallstudier
  • Webbinarier

Företag

  • Om oss
  • Karriärer
  • Press
  • Kontakt
  • Partners

Våra kontor

  • New York, HQ
  • Bukarest, AI-forskningslabb
  • Zug, Schweiz

© 2026 Salestools. Alla rättigheter förbehållna.

Datavillkor och SäkerhetSekretesspolicyAnvändarvillkorAcceptable Use
Alla system fungerar
Salestools LogoSalestools
Salestools AI-agenter
Lösningar
Resurser
Företag
Priser
Back to Reports
Fundraising

Verily Life Sciences

Verily Life Sciences Raises $1B in Series D

South San Francisco, CAJanuary 12, 20222 min read
Employees
1500+

Verily Life Sciences Raises $1B in Series D


Verily Life Sciences has successfully raised $1B in a Series D at a $6B valuation led by Temasek, Silver Lake, Ontario Teachers.


Company Overview


Verily Life Sciences is a HealthTech company headquartered in South San Francisco, CA, founded in 2015 with 1500+ employees.


Precision health and life sciences research


Fundraising Details


  • Amount Raised: $1B
  • Round Type: Series D
  • Valuation: $6B
  • Date: 2022-01-12
  • Investors: Temasek, Silver Lake, Ontario Teachers

About Verily Life Sciences


Precision health and life sciences research The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: South San Francisco, CA
  • Founded: 2015
  • Team Size: 1500+
  • Industry: HealthTech

What This Means


This funding round demonstrates strong investor confidence in Verily Life Sciences's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Verily Life Sciences's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $6B valuation marks an important milestone for Verily Life Sciences, positioning the company among notable players in the HealthTech industry.


Looking Ahead


With this new capital, Verily Life Sciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2022-01-12. For more information about Verily Life Sciences, visit their headquarters at South San Francisco, CA.

Company Info

Headquarters
South San Francisco, CA
Founded
2015
Team Size
1500+

Topics

Fundraising(2912)HealthTech(503)Series D(267)Verily Life Sciences

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free